CARLSBAD, Calif., Feb. 8, 2012 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. /quotes/zigman/74162/quotes/nls/isis ISIS -2.63% , the leader in antisense therapeutics, today announced that management will present a company overview at Leerink ...

San Diego County's life science sector added employees during the recession at a brisk pace, according to a new report from Biocom, a San Diego-based life science trade group that covers Southern California.

Biogen Idec Inc. (BIIB) may ultimately join Amgen Inc. (AMGN) as biotechnology companies that pay a dividend, Chief Financial Officer Paul Clancy said.

Up 1.7% to $7.98, Isis Pharmaceuticals (NASDAQ:ISIS), is one of today's notable movers. The S&P is trading fractionally higher to 1315 and the Dow is trading fractionally lower to 12672.

(RTTNews) - Cancer is the second most common cause of death in the US, exceeded only by heart disease, accounting for nearly 1 of every 4 deaths, according to the American Cancer Society.

Do you like knowing whether a company has a lot of cash relative to its operating expenses? If you doubt a company's ability to make consistent profits, it may be comforting to know whether it at least has the cash to sustain operations.

Vancouver, BC - Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that Alnylam Pharmaceuticals, Inc. (“Alnylam”) filed a patent infringement lawsuit against Tekmira in ...

Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) has brought a patent infringement suit against Tekmira Pharmaceuticals Corp. over using patents related to using small interfering RNA (siRNA) molecules in a drug development deal.

By Robert Weisman SAN FRANCISCO - In long days packed with back-to-back meetings last week, Tillman Gerngross pressed drug company leaders from around the world to farm out some specialized research and development to his New Hampshire start-up, ...

CHICAGO, Jan. 13, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.